Solventless method for forming a coating on a medical electrical lead body

• US 8,753,708 B2
• Filed: 07/08/2010
• Issued: 06/17/2014
• Est. Priority Date: 09/02/2009
• Status: Active Grant

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Hum, Larry L., Feng, James Q., Simon, Arienne P., Tas, Tolga
• Primary Examiner(s): Yuan, Dah-Wei D
• Assistant Examiner(s): BOWMAN, ANDREW J
• Application Number:
  US12/832,635
• Publication Number:
  US 20110052787A1
• Time in Patent Office: 1,440 Days
• Field of Search: 607/120, 623/1.34, 174/126.1, 264/250
• US Class Current: 427/2.1
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61L 31/18 Materials at least partially X-ray or laser opaque
• CPC Class Codes: C08L 83/04 Polysiloxanes
• CPC Class Codes: C09D 5/38 Paints containing free metal not provided for above in groups C09D5/00 - C09D5/36

Abstract

A solventless method for forming a coating on a medical electrical lead is described. The method includes combining particles of a therapeutic agent with a polymeric material in a flowable form in the absence of a solvent to form a uniform suspension. A predetermined amount of the suspension is dispensed onto a portion of the lead and is then cured to form the therapeutic agent eluting layer. Additional layers such as a primer layer, fluoro-opaque layer and/or a topcoat layer can be formed using the solventless method. Employing a solventless method may avoid contraction of the layer being formed due to solvent evaporation during the curing process, and may facilitate greater control over the thickness of the therapeutic agent eluting coating.

Claims

1. A solventless method for forming a therapeutic agent eluting coating on a medical electrical lead including a lead body comprising:

dispensing a predetermined amount of a solventless suspension onto an outer surface of the lead body in close proximity to at least one electrode located on the lead body using an automated syringe while rotating the lead body around its longitudinal axis, the suspension comprising up to about 20 wt % particles of at least one therapeutic agent dispersed within an uncured silicone medical adhesive having a viscosity ranging from about 0.001 Pas to about 20 Pas; and

moisture curing the suspension to form a polymer matrix layer that is free of residual solvent.

2. The method according to claim 1, wherein the therapeutic agent comprises an anti-inflammatory agent.

3. The method according to claim 1, wherein the therapeutic agent comprises an anti-proliferative agent.

4. The method according to claim 1, wherein the therapeutic agent comprises a combination of an anti-inflammatory agent and an anti-proliferative agent.

5. The method according to claim 1, wherein the therapeutic agent comprises dexamethasone or a derivative or salt thereof.

6. The method according to claim 1, wherein the suspension further comprises particles of a fluoro-opaque material.

7. The method according to claim 6, wherein the fluoro-opaque material comprises tungsten particles.

8. The method according to claim 6, wherein the fluoro-opaque material comprises platinum particles.

9. The method according to claim 1, further comprising the steps of:

dispensing a predetermined amount of an uncured admixture substantially free of solvent comprising an uncured silicone adhesive having a viscosity ranging from about 0.001 Pas to about 20 Pas and particles of a fluoro-opaque material onto the outer surface of the lead body at a location in close proximity to the at least one electrode using a motorized syringe while rotating the lead body around its longitudinal axis; and

curing the admixture to form a fluoro-opaque layer.

10. The method according to claim 9, wherein the fluoro-opaque material comprises tungsten or platinum particles.

11. The method according to claim 9, wherein an amount of fluoro-opaque particles in the admixture ranges from about 10 wt % to about 80 wt %.

12. The method according to claim 9, wherein an amount of fluoro-opaque particles in the admixture is at least 50 wt %.

13. The method according to claim 9, wherein an amount of fluoro-opaque particles in the admixture ranges from about 50 wt % to about 75 wt %.

14. The method according to claim 9, wherein the fluoro-opaque layer is formed over the polymer matrix layer.

15. The method according to claim 9, wherein the polymer matrix layer is formed over the fluoro-opaque layer.

16. The method according to claim 9, wherein the fluoro-opaque layer is formed over and in contact with the outer surface of the lead body.

17. The method according to claim 9, further comprising the steps of:

dispensing a predetermined amount of an uncured topcoat material in the absence of solvent onto the fluoro-opaque layer using a motorized syringe while simultaneously rotating the lead body; and

curing the topcoat material to form a topcoat layer disposed over and in contact with the fluoro-opaque layer.

18. The method according to claim 1, further comprising the steps of:

dispensing a predetermined amount of a primer material substantially free of solvent onto the outer surface of the lead body at a location in close proximity to the at least one electrode using a motorized syringe while rotating the lead body around its longitudinal axis;

curing the primer material to form a primer layer; and

thereafter, forming the polymer matrix layer over the primer layer.

19. The method according to claim 1, further comprising dispensing a predetermined amount of a primer material substantially free of solvent onto the outer surface of the lead body at a location in close proximity to the at least one electrode using a motorized syringe while rotating the lead body around its longitudinal axis, curing the primer material to form a primer layer, and thereafter forming a fluoro-opaque layer over and in contact with the primer layer.

20. The method according to claim 1, further comprising dispensing a predetermined amount of an uncured topcoat material in the absence of solvent onto the polymer matrix layer using a motorized syringe while simultaneously rotating the lead body.

21. The method according to claim 1, wherein a percentage of therapeutic agent in the suspension ranges from about 2 to about 20% (wt/wt).

22. A solventless method of forming a multi-layered coating on a medical electrical lead including a lead body comprising:

dispensing a predetermined amount of a solventless admixture comprising an uncured silicone adhesive having a viscosity ranging from about 0.001 Pas to about 20 Pas and particles of a fluoro-opaque material onto the outer surface of the lead body at a location in close proximity to the at least one electrode while rotating the lead body around its longitudinal axis;

curing the admixture to form a fluoro-opaque layer, wherein the fluoro-opaque layer comprises about 10 wt % to about 80 wt % of the fluoro-opaque material;

dispensing a predetermined amount of a solventless suspension comprising up to about 20% (wt/wt) of therapeutic agent particles distributed within the uncured silicone medical adhesive having a viscosity ranging from about 0.001 Pas to about 20 Pas over the fluoro-opaque layer using an automated syringe while rotating the lead body around its longitudinal axis; and

curing the suspension to form a polymer matrix layer that is free of residual solvent.

23. The method according to claim 22, further comprising dispensing a predetermined amount of an uncured topcoat material in the absence of solvent onto the fluoro-opaque layer using a motorized syringe while simultaneously rotating the lead body;

and curing the topcoat material to form a topcoat layer disposed over and in contact with the fluoro-opaque layer.

24. The method of claim 22, further comprising dispensing a predetermined amount of a primer material substantially free of solvent onto the outer surface of the lead body at a location in close proximity to the at least one electrode using a motorized syringe while rotating the lead body around its longitudinal axis, curing the primer material to form a primer layer, and thereafter forming the fluoro-opaque layer over and in contact with the primer layer.